Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Total Debt (2016 - 2022)

Historic Total Debt for Lexaria Bioscience (LEXX) over the last 12 years, with Q2 2022 value amounting to $7906.0.

  • Lexaria Bioscience's Total Debt rose 531.5% to $7906.0 in Q2 2022 from the same period last year, while for May 2022 it was $7906.0, marking a year-over-year increase of 531.5%. This contributed to the annual value of $7926.0 for FY2021, which is 9113.16% down from last year.
  • Lexaria Bioscience's Total Debt amounted to $7906.0 in Q2 2022, which was up 531.5% from $7875.0 recorded in Q1 2022.
  • Lexaria Bioscience's 5-year Total Debt high stood at $206806.0 for Q1 2021, and its period low was $1600.0 during Q1 2020.
  • In the last 5 years, Lexaria Bioscience's Total Debt had a median value of $9110.0 in 2018 and averaged $39041.4.
  • Its Total Debt has fluctuated over the past 5 years, first plummeted by 9802.06% in 2018, then surged by 1282537.5% in 2021.
  • Lexaria Bioscience's Total Debt (Quarter) stood at $21654.0 in 2018, then soared by 71.79% to $37200.0 in 2019, then surged by 217.3% to $118037.0 in 2020, then plummeted by 93.38% to $7817.0 in 2021, then rose by 1.14% to $7906.0 in 2022.
  • Its Total Debt was $7906.0 in Q2 2022, compared to $7875.0 in Q1 2022 and $7817.0 in Q4 2021.